Fresh analysis suggests that people who come off popular slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who end traditional diet and exercise plans.
Published data in a major medical journal demonstrates that while obese people can lose a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"People using these treatments should be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a reversion to pre-treatment mass within about 18 months.
Analyzing Treatments
The study, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through dieting usually have a less rapid weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Experts believe the way of the injections is key to understanding the accelerated rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Disease?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, given the significant potential of relapse, the treatment is often long-term.
This view is echoed by pharmaceutical companies, who state that the findings "highlight the long-term nature of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
Users who have come off the jabs explain a powerful resurgence of cravings.
"It was like a switch that goes on and I was suddenly extremely hungry," described an individual.
The struggle is exacerbated if users have not developed sustainable dietary or behavioural changes during therapy.
Widespread Interest
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a magic solution and long-term success hinges on combined behavioural changes.
